CALGARY, Feb. 6 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will participate as an invited speaker as part of a panel discussion entitled "Breaking Down the Barriers to New Neuro-Oncology Drugs" at the 10th Annual Bio CEO & Investor Conference 2008 on Monday, February 11 at 9:30 a.m. (ET). The conference, which is expected to draw more than 1,000 biotechnology and life sciences investors, will be held at the Waldorf-Astoria Hotel in New York City on February 11-13, 2008.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com
The presentation time is subject to change. This release and the
presentation related thereto contain forward-looking statements which
involve known and unknown risks, delays, uncertainties and other factors
not under the Company's control and which may cause actual results,
performance or achievements of the Company to be materially different from
the results, performance or expectations implied by these forward-looking
statements. Such risks and uncertainties include, among others, the
efficacy of REOLYSIN(R) as a cancer treatment, the success and timely
completion of clinical studies and trials, uncertainties related to the
research and development of pharmaceuticals, uncertainties related to the
regulatory process and general changes to the economic environment.
Investors should consult the Company's quarterly and annual filings with
the Canadian and U.S. securities commissions for a
|SOURCE Oncolytics Biotech Inc.|
Copyright©2008 PR Newswire.
All rights reserved